First Trust Advisors’s Pacific Biosciences PACB Stock Holding History

First Trust Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,896	Closed	-$41.9K	–	2597
2024 Q4	$41.9K	Buy	+22,896	New	+$44.7K	﹤0.01%	2545
2024 Q2	–	Sell	-39,974	Closed	-$150K	–	2397
2024 Q1	$150K	Buy	39,974 +25,366	+174%	+$149K	﹤0.01%	2293
2023 Q4	$143K	Sell	14,608 -191,663	-93%	-$1.57M	﹤0.01%	2317
2023 Q3	$1.72M	Buy	206,271 +1,492	+0.7%	+$17.1K	﹤0.01%	1745
2023 Q2	$2.72M	Buy	+204,779	New	+$2.49M	﹤0.01%	1558
2021 Q4	–	Sell	-114,037	Closed	-$2.91M	–	2577
2021 Q3	$2.91M	Sell	114,037 -34,223	-23%	-$1.01M	﹤0.01%	1612
2021 Q2	$5.18M	Buy	+148,260	New	+$4.31M	0.01%	1338
2017 Q1	–	Sell	-97,396	Closed	-$370K	–	2438
2016 Q4	$370K	Buy	+97,396	New	+$708K	﹤0.01%	2220
2016 Q3	–	Sell	-127,934	Closed	-$900K	–	2374
2016 Q2	$900K	Buy	+127,934	New	+$1.17M	﹤0.01%	1759

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors's PACB Position: Q1 2025 in Review

First Trust Advisors sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 22,896 shares — an estimated $41.9K sold.

First Trust Advisors first reported a position in PACB in Q2 2016 and held it in 9 quarters. The position peaked at $5.18M in Q2 2021. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

First Trust Advisors reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
First Trust Advisors sold 22,896 Pacific Biosciences shares in Q1 2025, an estimated $41.9K.
First Trust Advisors first reported a position in Pacific Biosciences in Q2 2016 and held it in 9 quarters.
First Trust Advisors's Pacific Biosciences position peaked at $5.18M in Q2 2021.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on First Trust Advisors's 13F filing for Q1 2025, filed 14 May 2025.